Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels ...

Nordstrom Rack has dropped some huge markdowns on Brooks running shoes and now you can grab a pair for up to $80 off.. Here are the best deals from this unbelievable sale ...

The global sales of the phlebotomy equipment market are estimated to be worth USD 14.69 billion in 2025 and are anticipated ...

Takeda licenses late-stage polycythemia vera drug candidate rusfertide from Protagonist Therapeutics, adding to its rare blood disorder pipeline.

About the Issue: Scoda Tubes is launching its maiden IPO via the book-building route, offering 1.57 crore fresh shares to raise Rs 220 crore at a price band of Rs 130–Rs 140 per share. The issue, open ...

NEWARK, CA, USA & OSAKA, Japan & CAMBRIDGE, MA, USA I June 01, 2025 I Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...

Introduction. The increasing incidence of acute respiratory tract infections (RTI) leads to high mortality in children and adults worldwide. The RTI account for 56 million deaths in 2019 in all age ...